Release Date: May 1, 2025
Expiration Date: May 1, 2026
Activity Overview
Over the past decade, the treatment of biliary tract cancers (BTCs) has been fundamentally altered with the introduction of effective targeted and immunologic therapy approaches. Optimal treatment selection now depends on careful evaluation of various molecular alterations that may be present in individual cases.
This podcast features a discussion of emerging treatment options for HER2-positive BTC led by Rohit Gosain, MD; and Rahul Gosain, MD; that features a faculty expert in evaluating and treating these cancers.
Target Audience
This educational activity is directed toward US and global community medical oncologists, pathologists, oncology nurses, nurse practitioners, and advanced practice providers who manage patients with gastroesophageal adenocarcinoma and BTC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explore the molecular basis of HER2 overexpression in BTC, and evaluate the mechanisms of action of key new and novel agents
- Analyze pivotal trial results for HER2-targeted therapies, and discuss their integration into treatment decisions
Rahul Gosain, MD, MBA
Assistant Professor of Clinical Medicine
Medical Director, Wilmot Cancer Institute at Webster
Director, Wilmot Cancer Institute Regional Infusion Services
Wilmot Cancer Institute–Webster
University of Rochester Medicine
Rochester, NY
Disclosures: Consultancy/Advisory: AstraZeneca, Gilead, Janssen Oncology; Honorarium: Cor2ed, Integrity CE, MJH Life Sciences, Oncology News Central, SignifyMD.
Rohit Gosain, MD
Assistant Professor of Clinical Medicine
University of New York at Buffalo
Director of Roswell Park Care Network Southtowns
Roswell Park Comprehensive Cancer Center
Rochester, NY
Disclosures: Consultancy/Advisory: Eisai; Honorarium: Cor2ed, Integrity CE, MJH Life Sciences, Oncology News Central, SignifyMD.
Shubham Pant, MD, MBBS
Professor of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics
Director, Clinical Research
Associate Director, Early Phase Drug Development, Pancreatic Cancer Research
Sheikh Ahmed Center, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Consulting/Advisory Role: Alligator Bioscience, Arcus, AskGene Pharma, AstraZeneca, BMS, Boehringer Ingelheim, BPGBio, Ipsen, Janssen, Jazz Pharmaceuticals, Ltd, Merck, Nihon Medi-Physics Co, Novartis, Pfizer, Revolution Medicine, Theriva Biosciences, USWorldmeds, Zymeworks; Research Funding (paid to institution): Amal Therapeutics, Arcus, Astellas, Biontech, Boehringer Ingelheim, Bristol-Myers Squibb, Elicio, Framewave, Immuneering, ImmunoMET, Ipsen, Janssen, Jazz Therapeutics, Lilly, Mirati Therapeutics, NGM Pharmaceuticals, Novartis, Pfizer, Revolution medicine, Zymeworks; Stock: Telperian.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
